A Cytoplasmic Tail Determinant in HIV-1 Vpu Mediates Targeting of Tetherin for Endosomal Degradation and Counteracts Interferon-Induced Restriction by Kueck, Tonya & Neil, Stuart J. D.
A Cytoplasmic Tail Determinant in HIV-1 Vpu Mediates
Targeting of Tetherin for Endosomal Degradation and
Counteracts Interferon-Induced Restriction
Tonya Kueck, Stuart J. D. Neil*
Department of Infectious Disease, King’s College London School of Medicine, Guy’s Hospital, London, United Kingdom
Abstract
The HIV-1 accessory protein Vpu counteracts tetherin (BST-2/CD317) by preventing its incorporation into virions, reducing
its surface expression, and ultimately promoting its degradation. Here we characterize a putative trafficking motif, EXXXLV,
in the second alpha helix of the subtype-B Vpu cytoplasmic tail as being required for efficient tetherin antagonism. Mutation
of this motif prevents ESCRT-dependent degradation of tetherin/Vpu complexes, tetherin cell surface downregulation, but
not its physical interaction with Vpu. Importantly, this motif is required for efficient cell-free virion release from CD4+ T cells,
particularly after their exposure to type-1 interferon, indicating that the ability to reduce surface tetherin levels and promote
its degradation is important to counteract restriction under conditions that the virus likely encounters in vivo. Vpu EXXXLV
mutants accumulate with tetherin at the cell surface and in endosomal compartments, but retain the ability to bind both b-
TrCP2 and HRS, indicating that this motif is required for a post-binding trafficking event that commits tetherin for ESCRT-
dependent degradation and prevents its transit to the plasma membrane and viral budding zones. We further found that
while Vpu function is dependent on clathrin, and the entire second alpha helix of the Vpu tail can be functionally
complemented by a clathrin adaptor binding peptide derived from HIV-1 Nef, none of the canonical clathrin adaptors nor
retromer are required for this process. Finally we show that residual activity of Vpu EXXXLV mutants requires an intact
endocytic motif in tetherin, suggesting that physical association of Vpu with tetherin during its recycling may be sufficient
to compromise tetherin activity to some degree.
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Introduction
The downregulation of cell-surface immunomodulatory pro-
teins is a common theme in the evasion of innate and adaptive
immune responses by mammalian viruses. One host molecule
targeted by diverse enveloped viruses is tetherin (CD317/BST-2),
an interferon-induced dimeric type-II membrane protein, which
inhibits the release of nascent virions from the cell surface [1,2]. By
virtue of an unusual topology that consists of an N-terminal
transmembrane domain and a C-terminal glycophosphatidylino-
sitol (GPI)-linkage separated by an extended parallel coiled-coil
domain [3–6], tetherin partitions into budding virus particles and
is thought to directly cross-link the nascent virion to the plasma
membrane (PM) [7]. Tethered virions may then be endocytosed
and degraded in endosomes. Tetherin itself constitutively recycles
between the PM, endosomal and trans-Golgi network (TGN)
compartments through a non-canonical trafficking motif (YX-
YXXV) in its N-terminal cytoplasmic tail, which engages clathrin
adaptors AP-1 and AP-2 [8,9]. Since tetherin targets a structural
component of the virion not encoded by the viral genome, namely
the host-cell derived membrane, its potential importance in the
innate antiviral response is highlighted by multiple examples of
virally-encoded countermeasures (reviewed in [10]).
The ability to counteract tetherin is conserved among human
and simian immunodeficiency viruses (HIVs/SIVs), although the
viral proteins tasked with this activity vary [10]. In HIV-1 the
accessory protein Vpu fulfills this role. Vpu, a small integral
membrane phosphoprotein, directly associates with tetherin
through interactions between the transmembrane domains of
both proteins [11–14]. Vpu blocks tetherin incorporation into
assembling virions [7] and leads to a reduction of tetherin levels on
the plasma membrane (PM) [2]. Subsequently, tetherin is
degraded, most likely in lysosomal compartments, by an
ubiquitin-dependent mechanism [15,16]. Phosphorylation of
Vpu on two conserved serine residues recruits a SCF b-TrCP1/
2 E3 ligase complex [17] that ubiquitinates the tetherin
cytoplasmic tail on multiple residues [18], and recent evidence
demonstrates that this tetherin degradation is dependent on the
ESCRT pathway [19]. However, tetherin degradation is not
strictly required for Vpu activity [20,21]. While recruitment of the
ESCRT-0 subunit HRS by Vpu counteracts tetherin activity [19],
a novel core component of ESCRT-1, Ubiquitin Associated
Protein 1 (UBAP1), essential for tetherin degradation induced by
both Vpu and the KSHV ubiquitin ligase K5, is dispensable [22].
Coupled with recent evidence that dysregulation of the entire late
endosomal compartment by mutants of Rab7a [23], this suggests
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counteract its antiviral activity prior to lysosomal delivery. While
HIV-2 and SIV tetherin antagonists Env and Nef promote
tetherin internalization through their interactions with AP-2, [24–
26], Vpu does not enhance the rate of tetherin endocytosis
[13,16]. Rather it is thought that Vpu/tetherin interactions
preclude both the recycling of tetherin back to the cell surface
and the transit of newly synthesized tetherin to the PM by trapping
it in intracellular compartments, notably the TGN [13].
Consistent with this, the ability of Vpu to localize to the TGN
correlates with tetherin antagonism [27], and disruption of the
recycling compartment by a dominant Rab11a mutant compro-
mises Vpu activity [28]. Truncations of the Vpu cytoplasmic tail,
particularly the second alpha helix, lead to aberrant localization
and a reduction in its anti-tetherin activity, suggesting it harbors a
domain required for Vpu function [29].
In this study we have examined the role of the second alpha
helix of HIV-1 Vpu in tetherin antagonism. We identify a putative
sorting signal that is required for post-binding trafficking of Vpu/
tetherin complexes and inhibition of antiviral activity in primary
CD4+ T cells. While this signal can be functionally replaced by a
clathrin adaptor binding peptide derived form HIV-1 Nef, Vpu
activity does not require the canonical adaptors AP-1, AP-2 or AP-
3. Moreover, because residual activity of second helix mutants
requires an intact recycling signal in tetherin, we propose that
second alpha helix mutants are selectively defective for routing
tetherin into an endosomal degradation pathway thereby inhib-
iting its transit to the PM and incorporation into nascent virions.
Results
Determinants of tetherin inactivation in the second alpha
helix of the Vpu cytoplasmic tail
Truncations of the Vpu cytoplasmic tail lead to aberrant
localization and a reduction in its anti-tetherin activity [29]. To
further study the determinants within the second alpha helix of
Vpu that account for TGN localization, we performed overlap-
ping triple-alanine scan mutagenesis through the second alpha
helix of a codon optimized HIV-1 NL4.3 Vpu construct bearing a
C-terminal HA tag (Figure 1A). We then assayed these Vpu
mutants for their ability to rescue Vpu-defective HIV-1 from
tetherin restriction. 293T cells were transfected with wildtype
HIV-1 (HIV-1 wt) or Vpu defective HIV-1 (HIV-1 delVpu)
proviruses in combination with fixed doses of a human tetherin
expression vector, and 25 ng of Vpu-HA or mutant thereof. 48 h
after transfection cell lysates and supernatants were harvested and
analyzed for physical viral yield by Western blot (Figure 1B) or
supernatant infectivity of HeLa-TZMbl indicator cells (Figure 1C).
As expected, in the absence of Vpu, both supernatant particle yield
and infectivity of HIV-1 delVpu was profoundly reduced in the
presence of tetherin, expression of Vpu in trans rescued virus
production to wildtype levels. By contrast mutations encompassing
either E59 or L63 and V64 but not the intervening or subsequent
amino acids displayed defective rescue of HIV-1 delVpu (Figure 1B
and C). All Vpu mutants with the exception of Vpu 67-69A-HA
were expressed equivalently. Vpu 63-65A-HA appeared to display
a dominant interfering activity on HIV-1wt titer, but this was not
reflected as apparently in particle yield. Thus these data suggested
a functional requirement for E59 and L63/V64 in tetherin
antagonism by Vpu. To confirm this we mutated these residues to
alanine in the context of an HIV-1 NL4.3 provirus (NL4.3 Vpu
ELV) and examined viral release from 293T cells in the presence
of increasing expression of tetherin. Because this part of Vpu
overlaps with start of the Env open reading frame in the provirus,
these mutations were rendered silent in the +1 reading frame and
displayed no defect in virus release in the absence of tetherin
(Figure 1D and E). In agreement with the virus rescue in trans,
NL4.3 Vpu ELV release was markedly defective in the presence of
increasing tetherin doses, although it did display a residual
antagonism of tetherin when compared to the full Vpu-defective
deletion (Figure 1D and E).
We next examined the phenotypic basis for the defect in tetherin
antagonism by Vpu ELV. Vpu stimulates the ubiquitin-dependent
degradation of tetherin, most likely in lysozomal compartments. We
infected HT1080 cells stably expressing human tetherin bearing an
HA-tag in the extracellular domain (HT1080/tetherin-HA) with
VSV-G-pseudotyped HIV-1 wt, HIV-1 delVpu or HIV-1 Vpu
ELV at an MOI of 2 to ensure .90% cell infection. 48 h later the
cells were lysed and Western blotting performed for relative
tetherin-HA levels (Figure 2A). As expected, cells infected with
HIV-1wtshowed reduced steadystate levels oftetherin that was not
apparent in those infected with HIV-1 delVpu. Similarly, in cells
infected with HIV-1 Vpu ELV there was no evidence of tetherin
degradation, but interestingly there appeared to be enhanced levels
of tetherin, perhaps suggesting stabilization of the protein in the
presence of the mutantVpu. ThusE59, L63, V64mutations abolish
the ability of Vpu to induce tetherin degradation. Since this
degradation is dependent on Vpu binding to b-TrCP2 via a
phosphorylated pair of serines (S52 and S56) [16,17,30], we tested
whether Vpu ELV mutants were defective for interaction with b-
TrCP2 in co-immunoprecipitations from transfected cells
(Figure 2B). b-TrCP2 was co-immunoprecipitated with Vpu-HA
and Vpu ELV-HA, but as expected, not the phospho-mutant Vpu
2/6-HA, ruling out this defect in Vpu ELV.
Recent data suggests that ESCRT-mediated degradation of
tetherin in the presence of Vpu is mediated by interaction of Vpu
with HRS (ESCRT-0) [19]. We could further show that both Vpu
and Vpu ELV also co-precipitated with HA-HRS from transfected
293T cells (Figure 2C) indicating that an inability to recruit
ESCRT-0 does not explain the defect in Vpu ELV-mediated
degradation of tetherin.
Author Summary
Tetherin inhibits the release of several diverse enveloped
viruses from infected cells and is counteracted by the HIV-
1 accessory gene Vpu. Vpu prevents tetherin’s incorpora-
tion into nascent viral particles, promotes its downregu-
lation from the cell surface and targets tetherin for
degradation. Here we identify a determinant that resem-
bles an acidic-dileucine-based sorting sequence in the Vpu
cytoplasmic tail that is required for efficient counteraction
of tetherin activity, particularly in CD4+ T cells treated with
type-1 interferon. Mutation of this motif prevents cell-
surface downregulation and degradation of Vpu/tetherin
complexes but does not affect their interaction. Rather, in
its absence, Vpu accumulates in early endosomes and at
the cell surface where it becomes incorporated into
assembling virions with tetherin, indicating that this motif
modulates sub-cellular trafficking of tetherin. Furthermore
Vpu activity is clathrin-dependent and can be reconstitut-
ed by replacing a portion of the cytoplasmic tail
encompassing this motif with one derived from HIV-1
Nef that is known to bind several clathrin adaptors. Finally,
we demonstrate that residual function of the mutant Vpu
requires a trafficking motif in tetherin, suggesting that
physical interaction of tetherin with Vpu during its
recycling to the cell-surface can interfere with its function
to a variable extent.
A Trafficking Motif for Vpu/Tetherin Complexes
PLoS Pathogens | www.plospathogens.org 2 March 2012 | Volume 8 | Issue 3 | e1002609Figure 1. E59, L63 and V64 in the second alpha helix of the Vpu cytoplasmic tail are required to efficiently counteract tetherin. (A)
Schematic representation of alanine scan mutagenesis in the second alpha helix of the codon-optimized HIV-1 NL4.3 Vpu protein. (B) 293T cells were
transfected with NL4.3 wt or NL4.3 delVpu proviruses in combination with tetherin and the indicated pCR3.1 Vpu-HA expression vectors. 48 h post
transfection, cell lysates and pelleted supernatant virions were harvested and subjected to SDS-PAGE and analyzed by Western blotting for HIV-1
p24CA, Vpu-HA and Hsp90 serving as loading control, and analyzed by LiCor quantitative imager. (C) Viral supernatants from B were assayed for
infectivity using HeLa-TZMbl reporter cells. Infectious virus release is plotted on a log scale as b-galactosidase activity in relative light units (RLU). Error
bars represent standard deviations of the means of three independent experiments. (D) E59A, L63A and V64A mutations were inserted into the vpu
gene of the NL4.3 provirus referred to as NL4.3 Vpu ELV. 293T cells were transfected with NL4.3 wt, NL4.3 delVpu or NL4.3 Vpu ELV proviral plasmids
together with increasing doses of tetherin expression vector. The resulting infectivity was determined as in C, error bars represent standard
deviations of the means of three independent experiments. (E) Cell lysates and pelleted viral supernatants from 0 ng and 100 ng tetherin input from
D were subjected to SDS-PAGE and analyzed by Western blotting for HIV-1 p24CA and Hsp90, and analyzed by LiCor quantitative imager.
doi:10.1371/journal.ppat.1002609.g001
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downregulate surface tetherin levels. We first transfected HeLa
cells (that express tetherin constitutively) with Vpu-HA expression
vectors in combination with a GFP reporter. 48 h later surface
tetherin was assayed by flow cytometry in the GFP positive cells
(Figure 2D). As expected, wildtype Vpu expression reduced cell
surface tetherin levels. Vpu mutants bearing E59A, LV63,64A
mutations, or the full ELV mutant all displayed a reduced capacity
to downregulate surface tetherin levels (Figure 2D and S1A). To
confirm this in a relevant cell-type, we then infected CD4 positive
Jurkat T cells with HIV-1 wt, HIV-1 delVpu, HIV-1 Vpu ELV or
HIV-1 Vpu 2/6A. 48 h later, the cells were stained for surface
tetherin and co-stained for intracellular p24CA as a marker of
infection (Figure 2E). To discriminate between truly infected cells,
and those that acquired p24+ debris by exposure of cells to high
titre (MOI 1) of viral inoculum, we compared to cells exposed to
virus in the presence of 50 mM AZT (Figure S1C). Cultures
infected with HIV-1 wt showed clear downregulation of tetherin
on the surface of p24CA positive cells. By contrast, tetherin was
not downregulated from the surface of either HIV-1 delVpu, HIV-
1 Vpu 2/6A or HIV-1 Vpu ELV infected cells. Rather, tetherin
levels were raised on some infected cells, perhaps reflecting
accumulation of tethered virions on the cell surface. A similar
result was observed for HeLa cells infected with the same viral
stocks (Figure S1B), although in this case we could detect no
enhanced tetherin surface expression on cells infected with Vpu
Figure 2. Vpu ELV mutants are defective for tetherin degradation and cell-surface downregulation. (A) HT1080 cells stably expressing
tetherin-HA were infected with VSV-G-pseudotyped HIV-1 wt, HIV-1 delVpu or HIV-1 Vpu ELV at an MOI of 2. 48 h post infection, cells were harvested
and subjected to SDS-PAGE and analyzed by Western blotting for tetherin-HA, Vpu and Hsp90, and analyzed by LiCor quantitative imager. Relative
tetherin-HA levels are indicated below each lane. The blot shown is a representative example of 3 independent experiments. (B) 293T cells were
transfected with pCR3.1 Vpu-HA, Vpu 2/6A-HA, or Vpu ELV-HA in combination with pCR3.1 myc-b-TrCP2. 48 h post transfection, cells were lysed and
immunoprecipitated with anti-HA antibody. Lysates and precipitates were subjected to SDS-PAGE and analyzed by Western blotting for Vpu and
myc-b-TrCP2, and analyzed by ImageQuant. The star represents an unspecific band. (C) Similarly, 293T cells were transfected with pCR3.1 HA-HRS in
combination with Vpu-GFP or Vpu ELV-GFP expression constructs. Cell lysates were precipitated with an anti-HA antibody and analyzed as in C.( D)
HeLa cells were co-transfected with pCR3.1 Vpu-HA or indicated Vpu mutant in combination with a GFP expression construct. Cell surface staining for
endogenous tetherin was analyzed by flow cytometry 48 h post transfection. GFP positive cells were gated and tetherin levels (solid lines) were
compared to those of untransfected HeLa cells (dotted lines). Numbers indicate median fluorescence intensities of surface tetherin on transfected
cells. The solid peak in the upper middle histogram represents the binding of the isotype control. (E) Jurkat cells were infected with VSV-G-
pseudotyped HIV-1 wt, HIV-1 delVpu, HIV-1 Vpu ELV or HIV-1 Vpu 2/6A at an MOI of 1. 48 h post infection, cells were stained for cell surface tetherin
and intracellular p24CA, and analyzed by flow cytometry. Productively infected cells were identified by comparing with culture infected with the
same MOI in the presence of 50 mM AZT to control for p24CA uptake of the inoculum (Figure S1C).
doi:10.1371/journal.ppat.1002609.g002
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[31].
Vpu ELV mutants localize to early endosomal
compartments and the cell surface
The E59XXXL63V64 motif in Vpu resembles an acidic
dileucine sorting signal (D/E)XXXL(L/I/M/V) found in the
cytoplasmic tails of membrane proteins that traffic through
endosomal compartments (reviewed in [32]). We therefore
addressed whether mutation of this motif affected Vpu subcellular
localization. To this end we infected 293T expressing tetherin or
not, as well as Jurkat and HeLa cells with VSV-G-pseudotyped
HIV-1 NL4.3 and NL4.3 Vpu ELV and stained them for Vpu in
combination with several subcellular markers 48 h later. As
expected, in all cells, the predominant localization of wildtype
Vpu was in association with the TGN, with between 20–50% of
the Vpu immunoreactivity visible in TGN46+ compartments
(Figure 3A–D). The proportion of the Vpu ELV mutant in
TGN46+ compartments was significantly reduced in 293T/
tetherin, Jurkat and HeLa, and appeared as ‘‘endosome-like’’
puncta in the cytoplasm and associated on or near the plasma
membrane (Figure 3A–C and E). Interestingly in the parental
293T cells, which lack tetherin expression, Vpu and Vpu ELV
localization was indistinguishable, and predominantly associated
with TGN46+ compartments (Figure 3D and E). Thus the
difference in Vpu ELV localization appeared to be tetherin-
dependent. The nature of these extra-TGN compartments was
further analyzed in HeLa cells and revealed that Vpu ELV
accumulated in EEA1+ early/sorting endosomal compartments,
but not CD63+ late endosomes (Figure 3F). Thus mutation of the
EXXXLV motif leads to endosomal and surface localization of
Vpu consistent with it being required for modulating the
trafficking of tetherin.
Vpu ELV mutants interact with tetherin in infected cells
and are incorporated into nascent virions in a tetherin-
dependent manner
As a putative trafficking signal, the EXXXLV motif may exert
its effect on tetherin antagonism in two ways. Firstly, the
sequence may be required to permit Vpu to traffic to a
compartment where it can interact with tetherin; secondly, the
sequence may be required for post-interaction trafficking of
Vpu/tetherin complexes such that tetherin is not incorporated
into budding virions and expression on the cell surface is
reduced. A potential confounding factor in investigating however
is that wildtype Vpu induces tetherin degradation, while Vpu
ELV does not. Whilst a Vpu 2/6 control maybe applicable,
controversies surrounding the nature of its phenotype in terms of
tetherin counteraction also make it problematic. To alleviate
these issues, we took advantage of our recent observations with
novel ESCRT-I component, UBAP1 [22]. UBAP1 contains 3-
tandem ubiquitin-binding domains and is found in complex with
the core ESCRT-I components TSG101, VPS28 and VPS36.
However unlike them, UBAP1 is only required for ESCRT-
dependent endosomal degradation and not viral assembly or
cytokinesis [22,33]. Interestingly, UBAP1 is essential for both
Vpu and K5-mediated degradation of tetherin, but is not
required for Vpu-mediated tetherin antagonism, implying that
commitment of tetherin into a degradative pathway by Vpu, but
not ESCRT-I function itself, counteracts tetherin activity [22].
We therefore first examined whether Vpu or Vpu ELV
interacted with tetherin in immunoprecipitations in the presence
or absence of siRNA-mediated silencing of UBAP1 by quanti-
tative Western blotting (Figure 4A). 293T/tetherin cells were
transfected twice over 48 h with either UBAP1 or control
siRNA, before being infected with HIV-1 wt, HIV-1 Vpu ELV,
HIV-1 delVpu, or HIV-1 Vpu A14L/W22A that contains a Vpu
transmembrane mutation that abolishes tetherin interaction
[14]. As expected, while tetherin levels were reduced in HIV-1
wt infected cells, they were unaffected by Vpu-defective or
A14L/W22A mutants and, as in Figure 2, stabilized in cells
infected with the Vpu ELV mutant. Furthermore, as expected,
UBAP1 siRNA treatment rescued tetherin levels from Vpu-
mediated degradation, but also further enhanced total cellular
levels of tetherin [22] consistent with the known role of ESCRT
in tetherin’s natural turnover [19]. Interestingly, UBAP1 siRNA
also enhanced the total cellular content of wildtype Vpu to that
of the Vpu ELV mutant (approximately 4–5 fold). Immunopre-
cipitation of tetherin from the lysates from these cells revealed a
similar picture. Wildtype Vpu was detected associated with
residual tetherin precipitated from cells, and this was markedly
increased upon UBAP1 knockdown. This data strongly suggests
that Vpu itself may be co-degraded with tetherin in endosomal
compartments. The Vpu ELV mutant efficiently co-precipitated
with tetherin irrespective of UBAP1 knockdown, and as expected
the A14L/W22A failed to co-precipitate under either condition.
Interestingly, however, the ratio of relative band intensities
between of Vpu or Vpu ELV precipitated with tetherin in the
presence UBAP1 siRNA was equivalent, indicating that Vpu
ELV was not defective for physical tetherin interaction,
suggesting that the Vpu ELV mutant’s defect in tetherin
antagonism is due to an inability to mediate post-binding
trafficking of Vpu/tetherin complexes into an ESCRT-depen-
dent pathway in which both proteins are degraded. Consistent
with this notion, Vpu ELV co-localized with tetherin in infected
HeLa and 293T/tetherin, both in peripheral endosomal
structures and at the cell surface (Figure 4B). By contrast, the
little tetherin visible in cells infected with wildtype virus co-
localized with Vpu in perinuclear areas.
Vpu is not a constituent of HIV-1 particles. We therefore
reasoned that if the EXXXLV motif was required to prevent
tetherin trafficking to viral budding sites and commit it for
degradation, interaction with tetherin itself might lead to Vpu
ELV mutant accumulation in nascent viral particles. To test this
hypothesis we took advantage of a tetherin mutant lacking its GPI
anchor (tetherin-delGPI), which despite its high surface expression,
does not restrict virus particle release, but accumulates in virus
particles and is sensitive to Vpu [7]. 293T/tetherin-delGPI cells
were mock-transfected or transfected with NL4.3 wt, NL4.3 Vpu
ELV, and NL4.3 delVpu. 48 h later cell supernatants were
centrifuged through a sucrose cushion and analyzed for tetherin
incorporation (Figure 4C and D). As expected, high levels of
tetherin-delGPI could be detected in NL4.3 delVpu viral pellets,
but not in pelleted supernatants from mock-transfected cells.
Tetherin-delGPI incorporation was reduced in the wildtype virus
consistent with tetherin removal from the cell surface. The level of
tetherin incorporation in NL4.3 Vpu ELV particles was similar to
that of the Vpu-defective mutant. Interestingly, NL4.3 Vpu ELV
particles contained detectable levels of Vpu (in this case Vpu
appears as a doublet band which we suggest may be due to
exposure to active HIV-1 protease in the particle). By contrast, no
Vpu was detectable in any viral particles derived from 293T cells,
indicating that Vpu ELV incorporation into viral particles was
tetherin-dependent. Taken together these data indicate that the
EXXXLV motif is required for efficient tetherin antagonism, by
modulating the trafficking of tetherin such that it cannot become
efficiently incorporated into nascent viral particles.
A Trafficking Motif for Vpu/Tetherin Complexes
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a D/EXXXLL-containing peptide derived from HIV-1 Nef
Acidic-dileucine based sorting signals, D/EXXXL(L/I), act as
binding sites for a hemicomplex of sigma and adaptin subunits of
the canonical clathrin adaptors AP-1, AP-2 and AP-3, and are
required for endocytic and endosomal/Golgi trafficking of these
proteins [32]. While the requirement for the acidic and first
leucine residues are absolute, the third position is less well
conserved, and can be L, I or on occasion V or M. Analysis of the
cytoplasmic tails of Vpu sequences from most clades of HIV-1
group M, show that a putative EXXXL(V/M/I) is well conserved
in the second alpha helix (Figure S2A). In contrast to other HIV-1
subgroups, Clade C and F isolates have an EXXXLL motif
juxtaposed to the plasma membrane in helix 1 (not shown), which
has been previously suggested to be a determinant of Clade C Vpu
localization to the PM [34]. In subgroup B, the V64 position is
usually V or M, although occasional I or L residues are found at
this position. We mutated position 64 to M, L or I in NL4.3 Vpu
and found no defect in these proteins’ ability to counteract or
downregulate tetherin from the surface (Figure S2B and S2C), in
agreement with the above data demonstrating that this position is
the least important of the three, and consistent with the role of this
motif as a sorting signal.
The Nef proteins of primate immunodeficiency viruses are also
multifunctional adaptor proteins, targeting a variety of immuno-
regulatory cell surface molecules for downregulation and degra-
dation [35]. Nef interacts promiscuously with AP-1, AP-2 and AP-
3 through a conserved C-terminal EXXXLL motif [36,37]. The
interaction of AP-2 with this site is essential for Nef targeting of
CD4 for ESCRT-dependent lysozomal degradation [37], but Nef-
mediated downmodulation of Class I MHC molecules requires
AP-1 [38]. Importantly several SIV Nef proteins are also tetherin
antagonists [39,40] and again this is dependent on the EXXXLL
motif [26]. We therefore asked whether the C-terminus of HIV-1
Vpu could be functionally substituted with a known AP-binding
site from these proteins. The EVSALV motif of NL4.3 Vpu was
first replaced with the core AP-binding site from NL4.3 Nef,
ENTSLL (Figure 5A). Since this is similar to sites already tested in
the previous experiment shown in Figure S2, this Vpu was as
functional as the wildtype protein in virus rescue experiments
(Figure 5B and C). We then replaced the entire cytoplasmic tail of
Vpu from residue 58 with a 19 amino acid stretch derived from
Nef including the ENTSLL and a downstream dual-aspartic acid
motif that has been previously shown to stabilize AP-2 interactions
[41]. Remarkably, the Vpu/Nef chimeric protein substantially
recovered tetherin antagonistic activity (Figure 5B and C).
Moreover, this chimera also displayed improved tetherin down-
regulation from the surface of transfected HeLa cells (Figure 5D).
This activity was entirely dependent on the key amino acids
required for AP-interaction as a chimera in which E, LL and DD
positions were mutated to alanine was unable to counteract
tetherin or downregulate it from the surface (Figure 5B–D).
Examination of the subcellular distribution of Vpu-Nef or the
mutant fused to CherryFP suggested that the mutant was localized
more prominently to the PM consistent with a defect in trafficking
imparted by the mutation (Figure 5E). Thus Vpu function can be
substantially recovered by replacing its entire second alpha helix
with a promiscuous AP-binding (D/E)XXXL(L/I) sorting signal,
indicating that linking Vpu directly to the clathrin trafficking
machinery can restore its activity in absence of the second alpha
helix.
Tetherin antagonism by Vpu is clathrin-dependent, but
independent of canonical adaptor proteins that bind
acidic di-leucine motifs
The implication of putative clathrin adaptor sites in Vpu-
mediated tetherin antagonism led us to test whether inhibition of
clathrin function inhibits Vpu activity. Overexpression of the C-
terminal fragment of the neuronal adaptor AP180 (AP180c) that
inhibits clathrin/membrane interactions [42], which was recently
shown to inhibit tetherin downregulation from the surface [43],
specifically blocked Vpu-dependent particle release of HIV-1 wt
from 293T cells expressing tetherin (Figure 6A), indicating
clathrin-dependent subcellular trafficking is essential for Vpu
activity. Infectious yield could not be determined in this
experiment because AP180c overexpression inhibits envelope
processing and blocks clathrin incorporation into particles, which
has been shown to play a role in retroviral particle infectivity
[44,45]. Interestingly AP180c expression, like UBAP1 siRNA
treatment, enhanced total Vpu expression levels, indicating
clathrin-dependent transport is involved in the turnover of Vpu.
Visualization of Vpu-YFP localization in 293T/tetherin cells
overexpressing AP180c showed vesicular rather than peri-nuclear
localization similar to that seen in the same cells infected with
HIV-1 Vpu ELV (Figure 6B), and this was not apparent in the
parental (tetherin negative) 293T cells, suggesting again this
difference was driven by interaction with tetherin.
The similarities between the EXXXLV motif and acidic
dileucine sorting signals, and its functional replacement with the
promiscuous ENTSLL motif in HIV-1 Nef led us to test whether
the major known adaptors involved in trafficking of membrane
proteins between the PM, endosomes and Golgi compartments
were required for Vpu-mediated tetherin antagonism. Clathrin-
mediated endocytosis requires AP-2, whereas AP-3 controls early-
to-late endosomal/lysosomal trafficking. AP-1 plays a role in
trafficking of cargo between early endosomes and the TGN, with
evidence that it can function in either direction [32]. To this end
we examined the effects of siRNA-mediated silencing of AP-1 (AP-
1c1), AP-2 (AP-2m1), AP-3 (AP-3m1/AP-3d1). Depletion of AP-2
by RNAi in 293T/tetherin cells had only minor effects on Vpu-
dependent virus particle release, suggesting that unlike SIV Nef
and HIV-2 Env, and consistent with the reports that Vpu does not
enhance tetherin endocytosis, AP-2 activity is dispensable for Vpu-
mediated tetherin antagonism (Figure 6C). Similarly AP-3m1/AP-
3d1 depletion had no detectable effect on tetherin activity or Vpu-
mediated counteraction (Figure 6D). Furthermore, human tetherin
could also be downregulated from the surface of mouse fibroblasts
defective in AP-3d1 when transduced to express Vpu [46] (Figure
S3A). For AP-1, siRNA-mediated silencing was inefficient in 293T
(not shown). We therefore constructed a HeLa cell line containing
a doxycycline-inducible shRNA hairpin against AP-1c1. Induction
of this hairpin coupled with simultaneous depletion of AP-1c1b y
Figure 3. Vpu ELV mutants localize to early endosomal compartments in tetherin-expressing cells. 293T/tetherin (A), HeLa (B), Jurkat
(C) or parental 293T (D) were infected with HIV-1 wt or HIV-1 Vpu ELV at an MOI of 1. 48 h later the cells were fixed and stained for Vpu (green) and
the TGN marker TGN46 (red) and examined by confocal microscopy. Panels are of representative examples. (E) The percentage of the total Vpu
immunoreactivity localized to TGN46+ compartments was calculated for cells (n=20) from A–D using the Leica Confocal Software. Results were
analyzed by unpaired 2-tailed t-test - ** P=10
28 or lower. (F) HeLa cells as in B were stained for Vpu (green) and the early endosomal marker EEA1 or
late endosomal marker CD63 (red).
doi:10.1371/journal.ppat.1002609.g003
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PLoS Pathogens | www.plospathogens.org 7 March 2012 | Volume 8 | Issue 3 | e1002609Figure 4. Vpu ELV interacts and colocalizes with tetherin, and is incorporated into nascent virions. (A) 293T/tetherin cells were
transfected twice over 48 h with siRNA oligonucleotide directed against UBAP1 or Non-targeting control. The cells were then infected with the
indicated virus at an MOI of 2. 48 h later cell lysates were immunoprecipitated with an anti-tetherin monoclonal antibody. Lysates and
immunoprecipitates were separated by SDS-PAGE and blotted for tetherin, UBAP1 or Vpu using LiCor quantitative Western blotting. Numbers under
the Vpu lanes of the cell lysate represent relative band intensities. The histogram below the IP represents the ratio of tetherin band intensity to that
of Vpu in the co-IP. (B) HeLa and 293T/tetherin cells were infected as in Figure 3 and stained for Vpu (green) and tetherin (red) and examined by
confocal microscopy. Adjacent histograms quantify the degree of co-localization of Vpu ELV and tetherin (Pearson’s Correlation Coefficient calculated
using ImageJ) for 20 individual cells. (C) and (D) 293T or 293T cells stably expressing tetherin delGPI were infected with HIV-1 wt, HIV-1 Vpu ELV or
HIV-1 delVpu at an MOI of 1. 48 h post infection, cells were harvested and viral supernatants were pelleted through a 20% sucrose cushion. Cells and
virions were subjected to SDS-PAGE and Western blotting for tetherin delGPI, Vpu, HIV-1 p24CA and Hsp90 and analyzed by LiCor quantitative
imager.
doi:10.1371/journal.ppat.1002609.g004
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PLoS Pathogens | www.plospathogens.org 8 March 2012 | Volume 8 | Issue 3 | e1002609Figure 5. The second alpha helix of Vpu can be functionally replaced by the D/EXXXLL endocytic signal from HIV-1 Nef. (A)
Schematic representation of Vpu ENTSLL and Vpu-Nef chimeric constructs. (B) 293T cells were transfected with NL4.3 wt of NL4.3 delVpu proviral
plasmids in combination with tetherin and indicated pCR3.1 Vpu-HA or Vpu-Nef-HA chimera. 48 h post transfection, cell lysates and pelleted
supernatant virions were harvested and subjected to SDS-PAGE and analyzed by Western blotting for HIV-1 p24CA, Vpu-HA and Hsp90, and analyzed
by LiCor quantitative imager. (C) Infectivity of viral supernatants from B was determined on HeLa-TZMbl cells as in Figure 1B. Error bars represent
standard deviation of three independent experiments. (D) HeLa cells were co-transfected with Vpu or indicated Vpu mutant and a GFP expression
construct. Cell surface staining for endogenous tetherin was analyzed by flow cytometry 48 h post transfection, as in Figure 2D. (E) HeLa cells were
transfected with Vpu-Nef or Vpu-Nef-mu CherryFP fusions (red) and counterstained for TGN46 (green) and DAPI (blue) and examined by confocal
microscopy.
doi:10.1371/journal.ppat.1002609.g005
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PLoS Pathogens | www.plospathogens.org 9 March 2012 | Volume 8 | Issue 3 | e1002609Figure 6. AP180c inhibits Vpu-mediated tetherin antagonism but AP-1, AP-2, AP-3 and retromer are dispensable. (A) 293T/tetherin
were transfected with NL4.3 wt or NL4.3 delVpu proviral plasmids in combination with either YFP or increasing doses of an AP180c expression vector.
48 h post transfection, cell lysates and pelleted supernatant virions were harvested and subjected to SDS-PAGE and analyzed by Western blotting for
HIV-1 p24CA, Vpu and Hsp90 serving as loading control, and analyzed by LiCor quantitative imager. (B) 293T or 293T/tetherin transfected with pCR3.1
Vpu-YFP with or without AP180c co-expression were fixed and imaged after 48 h (C) 293T cells stably expressing tetherin were transfected twice with
pooled control or AP-2m1 siRNAs and co-transfected with NL4.3 wt, NL4.3 delVpu or GFP expression vectors. Cell lysates and supernatants were
analyzed by Western blotting 48 h later as described in Figure 1B. (D) 293T cells stably expressing tetherin were transfected twice with pooled control
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efficiency. This treatment had no specific effect on Vpu-dependent
virus particle yield in HeLa cells indicating that tetherin-
antagonism again was not compromised (Figure 6E), and
furthermore tetherin surface downregulation was not defective in
mouse AP-1c1a 2/2 fibroblasts (Figure S3B) [47].
Finally, we examined whether there was any role for the
retromer complex, in Vpu-mediated tetherin antagonism. Retro-
mer regulates retrieval and recycling of endosomal proteins to the
TGN and is known to act co-operatively or antagonistically with
AP-1 (reviewed in [48]). The retromer complex consists of several
sorting nexins (SNX), and a core complex containing cargo
binding component, Vps34, and two essential co-factors, Vps26
and Vps29. We performed siRNA-mediated knockdown of Vps26
(Figure 6F). At levels of knockdown that were sufficient to
relocalize the CD8-cation-independent mannose-6-phosphate
receptor (CD8-CI-M6PR) (Figure S3C), disruption of retromer
had no detectable effect of Vpu-mediated HIV-1 release from
293T/tetherin cells.
Taken together these data demonstrate that neither depletion of
individual cellular adaptor proteins known to bind to (D/
E)XXXL(L/I) motifs, nor disruption of retromer-mediated
endosome-to-TGN retrieval, were sufficient to recapitulate the
phenotype of the Vpu ELV mutant.
Residual function of Vpu ELV requires an intact recycling
signal in tetherin
Recent data suggests that Vpu blocks both the transit of de novo
synthesized tetherin to the cell surface as well as the recycling of
tetherin endocytosed from the plasma membrane, with the relative
importance of these processes currently a matter of debate.
Tetherin recycling requires a dual tyrosine YXYXXV motif in its
cytoplasmic tail that acts as a binding site for AP-2 (for
internalization) and AP-1 (for recycling via the Golgi) [8,9].
Mutation of this site enhances tetherin’s surface expression, but
has minor effects on its ability to restrict virus release or its
sensitivity to Vpu [11,13]. Given that the EXXXLV motif was
defective for post-binding inactivation of tetherin, but retained a
low residual activity against tetherin in transient transfection
assays, we asked whether Vpu ELV was differentially defective
against tetherin mutants bearing lesions in its own sorting
sequence. We infected 293T/tetherin and 293T/tetherin Y6,8A
cells with HIV-1 wt, HIV-1 delVpu and HIV-1 Vpu ELV at fixed
dose (MOI 1) and measured viral release 48 h later (Figure 7A and
B). Vpu-defective viral release was approximately 35-fold reduced
from 293T/tetherin cells compared to the wildtype virus, and as
expected NL4.3 Vpu ELV had an intermediate phenotype in this
assay (6 fold less release than wt). However, in 293T/tetherin
Y6,8A all residual antagonistic activity of Vpu ELV was abolished
with viral release equivalent to that of the Vpu-deleted virus. By
contrast the wildtype virus retained the majority of its anti-tetherin
activity. This again was not due to a defect of Vpu interaction with
tetherin, as immunoprecipitation of tetherin after UBAP1 siRNA
treatment demonstrated equivalent levels of Vpu and Vpu ELV
co-precipitation from both tetherin and tetherin Y6,8A expressing
cells (Figure 7C). Thus residual activity of Vpu ELV requires that
tetherin retains its capacity to recycle from the PM. These data
suggest that Vpu ELV is specifically defective in blocking tetherin
transit to the PM, implying that Vpu/tetherin complexes are re-
routed in a Golgi-associated compartment into a pathway that
ultimately results in tetherin’s endosomal destruction. In the
absence of the EXXXLV sequence, tetherin/Vpu ELV complexes
traffic to the PM. The residual activity of Vpu ELV therefore may
be reflective of steric inhibition of tetherin function.
The dominant-negative mutant of dynamin 2 (K44A) has also
been described to have an intermediate effect on tetherin
counteraction by Vpu, compared to the complete disruption of
HIV-2 Env function which, like SIV Nef, is dependent on AP-2
and endocytosis [43]. We transfected increasing doses of HA-
tagged dominant negative dynamin 2 or the wildtype protein
along with HIV-1 proviruses into 293T/tetherin and parental cells
(Figure S4A). In agreement with Lau et al [43] dominant negative
dynamin 2, but not equivalent levels of the wild type dynamin 2
partially blocked the release of wildtype HIV-1 (Figure S4A–D).
Furthermore dominant negative dynamin 2 expression levels in
these assays were sufficient to block transferrin uptake in parallel
cultures (Figure S4B). Interestingly dominant negative dynamin 2
also blocked residual Vpu ELV-mediated, and even the low level
Vpu-defective viral release proportionally (7X, 4X and 8X for
WT, Vpu-defective or Vpu ELV respectively), suggesting that this
effect was independent of the ELV motif. Given that dominant
negative dynamin 2 inhibits tetherin endocytosis [43], this data
suggests that its effect on restriction may be due more to the build
up of tetherin at the cell surface that cannot be turned over rather
than a direct effect on Vpu function itself.
Vpu ELV is defective for tetherin antagonism in CD4+ T
cells after treatment with type-1 interferon
The results presented hitherto have demonstrated a require-
ment for the Vpu ELV motif in counteracting tetherin in cells
stably expressing it or mutants thereof, and that its is required in
constitutively-expressing target cells such as Jurkat to reduce
surface tetherin levels. However some studies have cast doubt as to
whether tetherin degradation and/or surface reduction is essential
for Vpu function. Furthermore, in contrast to 293T/tetherin,
release of HIV-1 Vpu ELV from HeLa was only 3-fold less
efficient than wildtype in one round release (Figure S5). We
therefore explored whether there was a requirement for the ELV
motif in HIV-1 release from physiologically relevant target cells,
namely Jurkat or primary human CD4+ T cells, particularly after
treatment with type-1 interferon. Infection of Jurkat at an MOI of
1 resulted in a partial defect in release of the HIV-1 Vpu ELV
mutant compared to the controls (Figure 8A and B). However
induction of higher tetherin expression by overnight treatment
with universal type-1 interferon effectively reduced HIV-1 Vpu
ELV particle release to levels similar to that of the Vpu-defective
control while only reducing the wildtype release moderately.
Similarly interferon treatment of purified activated human CD4+
T cells led to a selective defect in the production of cell-free HIV-1
Vpu ELV virions (Figure 8C) consistent with a concomitant
upregulation of surface tetherin levels (Figure 8D), and surface
tetherin downregulation (Figure 8E). Taken together with results
or siRNA pools against AP-3d1 and AP-3m1. 4 h post the second transfection the cells were infected with VSV-G-pseudotyped HIV-1 wt or HIV-1
delVpu virus stock at an MOI of 1. Cell lysates and supernatants were analyzed by Western blotting 48 h later as described in Figure 1B. (E) HeLa cells
expressing a doxycycline-inducible shRNA hairpin against AP-1c1were transfected twice with pooled control or siRNA pools against AP-1c1. The cells
were infected and analyzed as in C.( F) 293T cells stably expressing tetherin were transfected twice with pooled control or siRNA pools against the
retromer subunit Vps26. Cells were infected and analyzed as in C. In all siRNA knockdown experiments, the % knockdown of the indicated protein as
determined by the relative band intensity in the western is indicated below the blot panel.
doi:10.1371/journal.ppat.1002609.g006
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downregulate and degrade tetherin imparted by the EXXXLV
motif is required for cell-free virion release from relevant primary
HIV target cells, and becomes essential when tetherin expression is
enhanced by an antiviral stimulus.
Discussion
In this study we have identified a determinant within the second
alpha helix of the cytoplasmic tail of HIV-1 NL4.3 Vpu,
E59XXXL63V64, which is required for efficient antagonism of
tetherin. Mutation of this site blocks the ability of Vpu to mediate
tetherin downregulation from the cell surface and its ESCRT-
dependent degradation, but does not abolish its interaction with
tetherin, nor recruitment of b-TrCP2 or the ESCRT-0 component
HRS. Importantly, this motif is required to counteract tetherin in
CD4+ T cells, particularly after their exposure to type-I interferon.
Vpu ELV mutants localize to the cell surface and early/recycling
endosomal compartments rather than the TGN by virtue of their
interaction with tetherin. This is consistent with a role for this
determinant in Vpu-mediated inhibition of the transit of newly
synthesized and/or recycling tetherin to the cell surface, its
Figure 7. Residual activity of Vpu ELV requires an intact recycling signal in tetherin. (A) 293T/tetherin or 293T/tetherin Y6,8A mutant were
infected with VSV-G-pseudotyped HIV-1 wt, HIV-1 delVpu or HIV Vpu ELV at an MOI of 0.5. Supernatants and cell lysates were harvested 48 h later
and analyzed for infectious virus release on HeLa-TZMbl as in Figure 1C. (B) Corresponding Western blots of cell lysates and virions from A.( C) 293T/
tetherin Y6,8A cells treated with control or UBAP1 specific siRNAs were infected with VSV-G-pseudotyped HIV-1 wt, HIV Vpu ELV, HIV-1 Vpu A14L/
W22A or HIV-1 delVpu at an MOI of 2. 48 h post infection, cells were lysed and immunoprecipitated with an anti-tetherin antibody. Lysates and
immunoprecipitates were subjected to SDS-PAGE and analyzed by Western Blotting for tetherin, UBAP1 and Vpu, and analyzed by LiCor quantitative
imager. Ratios of Vpu/tetherin band intensities in the coIP are plotted on the histogram below.
doi:10.1371/journal.ppat.1002609.g007
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tion. However, while we could functionally complement Vpu
function by grafting the D/EXXX(L/I/M) motif from HIV-1 Nef
in place of helix-2, we could detect no effect of depletion of the
canonical clathrin adaptor proteins AP-1, AP-2 or AP-3 on Vpu-
mediated tetherin antagonism. The inhibition by AP180c
overexpression, however, implicates clathrin function in Vpu-
mediated tetherin antagonism. Finally, residual Vpu ELV activity
against tetherin was entirely dependent on an intact recycling
motif in tetherin’s cytoplasmic tail, suggesting that this motif
differentially affects antagonism of newly synthesized tetherin
rather than pre-existing pools recycling to the PM. These results
are in contrast to the recent study by Lau et al who were unable to
demonstrate a phenotype for an LV63,64AA mutant despite
interfering with Vpu activity with AP180c [43]. Given that we
have demonstrated phenotypes in several cellular systems
including CD4+ T cells for the Vpu ELV mutant, the reason for
this discrepancy is unclear.
There has been much debate as to whether the reduction of
tetherin levels at the plasma membrane is required to counteract
its antiviral activity, particularly in CD4+ T cells (reviewed in
[10]). In our hands, tetherin surface levels are reduced in HIV-1
infected primary T cells and Jurkat cells. However, under these
conditions, the viral release phenotype of the Vpu ELV mutant is
only a few-fold different than the wildtype protein. Interestingly
this changes upon treatment of the cells with type-I interferon,
which upregulates tetherin expression levels. In this case Vpu ELV
mutant release is reduced almost to that of the Vpu-defective virus,
but only minor further reductions are observed for the wildtype
virus. This therefore indicates that the requirement for surface
Figure 8. The EXXXLV motif is essential to counteract tetherin-mediated restriction of cell-free HIV-1 particle release from CD4+ T
cells treated with type-1 interferon. Jurkat cells were infected with the indicated HIV-1 mutant at an MOI of 1. 16 h later the cells were treated or
not with 5000 U/ml universal type-I interferon. Cell lysates and viral supernatants were harvested a further 24 h later and analyzed for infectivity on
HeLa-TZM (A) or physical particle yield and cellular viral and tetherin expression by quantitative Western blotting (B). (C) A representative example of
primary human CD4+ T cells treated as in (B) and the MFI of surface tetherin levels on these cells with or without 24 h type-I interferon treatment as
analyzed by flow cytometry (D). (E) Human CD4+ T cells were infected with the indicated virus. 48 h later cells were stained for surface tetherin and
intracellular p24CA and analyzed by flow cytometry.
doi:10.1371/journal.ppat.1002609.g008
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at higher expression levels of the restriction factor (something that
has been suggested previously by Goffinet et al [49]). Recent
conflicting data have addressed the effect of tetherin and
interferon on cell-cell transmission between T cells [50,51], which
when taken together show that if tetherin does restrict this mode of
virion transfer, it is far less efficient than its effect on cell-free viral
release. Thus, the fact that tetherin antagonism is such a highly
conserved attribute amongst primate immunodeficiency viruses
implies its importance in vivo. Since interferon treatment of CD4+
T cells magnifies the defective phenotype of a Vpu ELV mutant,
the ability to mediate tetherin’s surface reduction and target it for
endosomal degradation is likely to be essential for the virus to
avoid restriction under proinflammatory conditions it is likely to
encounter in vivo, particularly during acute infection [52,53].
Our results are consistent with the notion that Vpu blocks
delivery of tetherin to the plasma membrane [13,54] and suggest
that Vpu exerts its effect on tetherin trafficking in the TGN/
recycling compartment in a manner determined in part by this
putative sorting sequence. It is now clear that Vpu-mediated
tetherin degradation is ubiquitin-dependent and occurs in
lysosomes rather than early reports of proteasomal processing
[15,16], and that this process requires the ESCRT pathway [19].
Depletion of both TSG101 and Vps4 inhibits Vpu-mediated
tetherin degradation, and recruitment of HRS (ESCRT-0) has
been reported to be required for Vpu-mediated tetherin
antagonism [19], as has ubiquitination on multiple residues in
the tetherin cytoplasmic tail [18]. However tetherin’s ultimate
degradation itself is not essential for Vpu or other lentiviral
countermeasures to inactivate it. Our recent observations with the
novel ESCRT-I subunit, UBAP1, ([22] and the results presented
herein), demonstrate that ESCRT-I function is unlikely to be
required for tetherin antagonism, but its commitment to
endosomal degradation is. Interestingly, the concomitant enhance-
ment of wildtype Vpu levels, both co-precipitating with tetherin
and at steady state, suggest that Vpu is likely co-degraded with its
target.
Alongside the current literature our data suggests that Vpu
interaction with tetherin leads to a differential trafficking of
tetherin in the TGN and/or recycling compartments rather than
enhancing tetherin internalization (Figure 9). This inhibits forward
trafficking of either recycling or newly synthesized tetherin to the
PM, and commits it to a pathway that ultimately targets it to
endolysosomal compartments for degradation. We suggest that it is
this commitment, regulated by the EXXXLV motif in second
helix, rather than degradation per se, that is principally responsible
for antagonizing tetherin. Where Vpu interacts with tetherin in the
cell is likely to be related temporally to the viral replication cycle,
tetherin expression level, and its natural turnover rate. Vpu is
expressed ‘‘late’’ in replication from the same mRNA as Env [55],
at the time new virions are being built. Thus Vpu must deal with
two pools of tetherin; pre-existing protein in the periphery
recycling via the TGN [9], and de novo synthesized tetherin
trafficking through the Golgi en route from the endoplasmic
reticulum (ER) to the surface. Therefore we predict that Vpu
must interact with tetherin in TGN-associated compartments to
engage these two pools of tetherin, although our recent data
suggests that binding to newly synthesized tetherin may occur
prior to this in the ER [14]. Thereafter, a clathrin-dependent
sorting event determined by the helix-2 EXXXLV motif precludes
Vpu/tetherin complexes transiting to the PM. This intracellular
sequestration of tetherin is further coupled to late endosomal
targeting and ESCRT-dependent degradation through the
recruitment of HRS and tetherin ubiquitination [18,19]. In line
with this, global disruption of early to late endosomal transition by
dominant negative Rab7a also appears to inhibit Vpu activity
[23]. Interestingly, ubiquitinated cargo destined for ESCRT-
dependent degradation via HRS recruitment has been shown to
partition differentially to areas of early/sorting endosomal
membranes rich in flat clathrin lattices, thereby anchoring it
away from the recycling machinery [56]. Recruitment of tetherin
into such structures in the sorting compartment may be sufficient
to antagonize its function, offering an explanation as to why
clathrin is essential for Vpu activity but dynamin 2 mutants only
effect the residual activity of Vpu ELV. Because Vpu activity was
insensitive to retromer (Vps26) depletion, which is essential for
endosome-to-TGN retrieval and recycling [48], we suggest that
Vpu targets tetherin into this pathway from the TGN to
endosomal compartments, and an ensuing swift degradation
accounts for the observed sequestration in TGN46 positive
compartments. In the absence of the EXXXLV motif, tetherin
is not committed to this differential sorting in the TGN, and Vpu/
tetherin complexes are targeted to the cell surface and thereafter
back into the recycling system, accounting for the localization of
Vpu ELV in infected cells and its incorporation into virions.
Therefore in addition to acting as an adaptor for the recruitment
of ESCRT-0 and E3 ubiquitin ligase activity to tetherin, we
propose that through the EXXXLV motif, Vpu directly
chaperones associated tetherin molecules into an endosomal
compartment from which they cannot recycle to the PM.
EXXXLV mutants retain some residual antagonistic activity
that is entirely dependent on the AP-1/AP-2-binding motif in
tetherin. This would suggest that the action of the EXXXLV motif
does not solely account for the inhibition of tetherin by Vpu. Vpu
ELV still interacts with b-TrCP2, suggesting that tetherin
ubiquitination, which is important for counteracting its activity
[18], may still take place during the recycling process and effect
antiviral function. Also physical interaction between Vpu and
tetherin may be sufficient to interfere with some level tetherin
function provided tetherin can still associate with the clathrin-
dependent endocytic machinery. Since biochemical evidence
strongly favors a direct cross-linking model for tetherin’s antiviral
activity [7], either of these processes could in principle affect the
qualitative nature of tetherin distribution at viral assembly
domains at the PM such that tethers do not form efficiently,
something that is plausible in the light of Habermann et al’s
quantitative Cryo-EM analysis of tetherin localization at the PM in
infected HeLa cells [57]. The relative efficiency of this ‘‘second-
ary’’ inhibition of tetherin activity will thus be dependent on
cellular tetherin levels and the temporal stage of viral replication
(ie: the expression level of Vpu). Since Vpu-defective mutants of
HIV-1 in some studies show enhanced cell-to-cell transmission and
that tetherin may play a role in virological synapse formation
[51,58,59], such a differential effect on de novo synthesized versus
the recycling pool tetherin may favor viral transmission during
early stages of viral production, but effectively antagonize
induction of tetherin expression and potent restriction by a pro-
inflammatory response.
We have so far been unable to demonstrate direct interaction
between the Vpu EXXXLV motif and adaptors AP-1, 2 or 3 that
are known to bind acidic dileucine signals via a hemicomplex of
their sigma and adaptin subunits [32]. These interactions have
been demonstrated in yeast 3-hybrid assays previously for HIV-1
Nef [36,37], but not all interactions are amenable to this method
and in our hands the Vpu cytoplasmic tail is a constitutive
activator of transgene expression precluding its use. Furthermore,
the low affinity of these interactions, their transient nature, and the
complex interactions of the adaptor protein with membrane lipids
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tions from cells. The context dependency of (D/E)XXXL(L/I)
motifs that governs which adaptor they bind to in vivo is poorly
defined at present, meaning that RNAi-depletion is the most
reliable method for identifying the cellular factor involved. While
individual depletion of AP-1, 2 or 3 in our experiments had no
effect on Vpu-mediated tetherin antagonism, replacement of the
second alpha helix with the promiscuous AP-binding peptide from
HIV-1 Nef did recover function. This site in Nef is essential for
several functions including CD4 and MHC Class I downregula-
tion, the former being AP-2-dependent [37], the latter requiring
AP-1 [38]. Importantly, binding of AP-2 to this site in SIV Nef
proteins is required for their counteraction of non-human primate
tetherins [26]. Thus there are several possibilities. The EXXXLV
motif in Vpu might be a promiscuous AP-binding site and adaptor
usage may be redundant. The subcellular localization of tetherin/
Vpu ELV complexes in EEA1 positive endosomes and the partial
effect of dominant negative dynamin 2 would argue against a
significant role for AP-2, the major regulator of clathrin-mediated
transport from the PM. However toxicity associated with
simultaneous knockdown of multiple adaptors has precluded us
from addressing this possibility so far. Alternatively, replacement
of the second alpha with the Nef peptide recovers function because
it confers AP-2 binding to Vpu, thus allowing Vpu to counteract
tetherin in a manner similar to SIV Nef and HIV-2/SIV Envs that
both require AP-2 interactions [24–26,60]. However, these data
do underscore that linking Vpu to the clathrin trafficking
machinery promotes its ability to counteract tetherin.
If Vpu-mediated tetherin antagonism is clathrin-dependent, but
independent of AP-1, AP-2 or AP-3 (for which the importance of
clathrin is debated), what other adaptors might be important? Two
further heterotetrameric adaptors, AP-4 and AP-5, have been
identified, but understanding of their role in subcellular trafficking
is limited and at present they are not known to bind to acidic
dileucine motifs or to control clathrin-mediated transport [32,61].
The monomeric GGA (Golgi-associated, c-ear containing, ARF-
cofactors) 1–3 proteins that also function as clathrin adaptors that
regulate Golgi-to-endosome transport are potentially attractive
candidates, whose dysregulation has been reported to inhibit HIV-
1 assembly [62]. However, known GGA-binding motifs in cellular
cargoes correspond to a DXXLL consensus where the spacing of
the leucines from the acidic residue is thought critical.
The (E/D)XXXL(V/M/I) motif is conserved in Vpu proteins
from HIV-1 M group subtypes A, B, D, G and H (Figure S2), as
Figure 9. Model for the role of the EXXXLV motif in tetherin antagonism. Tetherin is expressed at the plasma membrane where it can
become incorporated into viral particles or recycles constitutively via early/sorting endosomal compartments and the TGN. Vpu interacts with
tetherin in the TGN (and perhaps earlier) through TM-domain-mediated interactions. In the presence of a functional EXXXLV motif, tetherin/Vpu
complexes are prevented from trafficking to the PM and routed for ESCRT-dependent endosomal degradation via a clathrin-dependent mechanism.
In the absence of an EXXXLV motif, tetherin/Vpu complexes recycle via the PM dependent on the YXYXXV sorting sequence in the tetherin
cytoplasmic tail, which interacts with AP-2 and AP-1. During the recycling process, physical interaction of Vpu and/or modification by ubiquitin
ligases, such as SCF-b-TrCP2, may further interfere with tetherin function to a variable degree in the absence of cell-surface downregulation.
doi:10.1371/journal.ppat.1002609.g009
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cannot antagonize tetherin [63], this maps to defective TM
domain-mediated interaction and the membrane proximal hinge
region. When replaced by those from a Group M Vpu these are
sufficient to confer tetherin inactivation implying that C-terminal
determinants retain function [64]. In Group M clades C and F, the
equivalent position is (D/E)XXXL(S/A) respectively, suggesting
that the site may not be functional in those Vpus, with the caveat
that the second position in the dileucine motif is less important.
Intriguingly both these subtypes bear EYXXL(L/I) motifs in the
membrane proximal region of their cytoplasmic tails that
encompass both a putative tyrosine and dileucine-based sorting
sequence. Evidence from Ruiz et al [34] has shown that a model
subtype C Vpu localizes to the PM rather than the TGN and that
this is in part due to this motif. While LL mutations in this subtype
C Vpu confer T-cell line replication phenotypes suggestive of a
failure to downmodulate tetherin, no direct experiments on the
role of this motif in tetherin-mediated HIV-1 release have been
thus far performed, nor whether this site can bind known clathrin
adaptors.
In summary our data implicate a trafficking determinant in the
Vpu cytoplasmic tail that is required for tetherin downregulation,
degradation and efficient antagonism, and suggest that it governs
differential sorting of Vpu/tetherin complexes in the TGN to
prevent forward transit of tetherin to the PM and viral budding
sites.
Materials and Methods
Cells and plasmids
HEK293T, HeLa and Jurkat cells were obtained from ATCC
(American Tissue Culture Collection). 293T/tetherin and 293T/
tetherin-delGPI and HT1080/tetherin-HA are cell lines stably
expressing human tetherin or mutant thereof, with or without a
hemagglutinin (HA) epitope tag inserted at nucleotide 463,
which has been previously described [1,65]. The reporter cell
line HeLa-TZMbl, was kindly provided by John Kappes through
the NIH AIDS Reagents Repository Program (ARRP). All
adherent cells were maintained in Dulbecco’s modified Eagle
medium (DMEM) (Invitrogen, UK) supplemented with 10%
fetal calf serum and Gentamycin; T-cell lines were grown in
Roswell Park Memorial Institute medium (RPMI) supplemented
with 10% fetal calf serum and Gentamycin. Murine fibroblasts
from pearl and AP1c1a deficient mice and derivative in which
AP3m or AP1c1a were re-expressed were kindly provided by
Andrew Peden [46] and Peter Schu [47] respectively. These cells
were transduced to express HA-tagged human tetherin using
pLHCX-THN-HA463 [65] and maintained in hygromycin
selection.
Wildtype HIV-1 NL4.3 (obtained from NIH-ARRP), a Vpu-
defective counterpart and pCR3.1 Vpu-HA containing a modified
codon optimized NL4.3 Vpu has been described previously [31].
All second alpha helix mutants of Vpu and mutations in the NL4.3
proviral genome were generated by Quick-change site-directed
mutagenesis PCR according to standard protocols using Phusion-
II polymerase (New England Biolabs). Vpu-Nef chimeras and
corresponding mutants were made with long reverse PCR primers
encoding Nef clathrin adaptor binding sites, cloned into pCR3.1
expression vectors encoding tagged or untagged tetherins which
have been described elsewhere [1]. b-TrCP2 was cloned from
HeLa cDNA and inserted into pCR3.1 with a C-terminal myc-tag.
pCR3.1 HA-HRS was kindly provided by Juan Martin-Serrano
[66]. pCR3.1 dynamin 2-HA and dominant negative dynamin 2-
HA have been previously described by [31].
Primary human CD4+ T cells were isolated from fresh venous
blood drawn from healthy volunteers. CD4+ T cells were purified
from total peripheral blood mononuclear cells (PBMC) isolated by
lymphoprep (AXIS-SHIELD) gradient centrifugation using a
CD4+ T cell Dynabeads isolation kit (Invitrogen). T cells were
then activated for 48 h using anti-CD3/anti-CD28 magnetic
beads (Invitrogen). The beads were then removed cells were then
maintained in rhIL-2 (20 U/ml) (Roche).
Production of viral and vector stocks
For full-length HIV-1 stocks pseudotyped with the Vesicular
Stomatitis Virus Glycoprotein (VSV-G), 293T cells were trans-
fected with 2 mg of proviral plasmid and 200 ng of pCMV VSV-
G. 48 h post-transfection, viral stocks were harvested and endpoint
titers were determined on HeLa-TZMbl cells as described below
[25].
Virus release assay
For transient-transfection-based virus release assays, subcon-
fluent 293T cells were plated on 24 well plates and transfected
with 500 ng proviral clone, in combination with 50 ng of tetherin
and 25 ng of Vpu-HA or mutants using 1 mg/ml polyethylenei-
mine (Polysciences). The medium was replaced 5 h and 16 h post-
transfection, cells were harvested after 48 h. The infectivity of viral
supernatants was determined by infecting HeLa-TZMbl, 48 h
later cells were assayed for b-galactosidase activity using the
chemiluminescence Tropix GalactoStar kit (Applied Biosystems).
For biochemical analysis of virus particle release, supernatants
were filtered (0.22 mm) and pelleted through a 20% sucrose/PBS
cushion at 20,000 g for 90 min at 4uC, and pellets were lysed in
SDS-PAGE loading buffer. Virion and cell lysates were then
subjected to SDS-PAGE and Western blotted for HIV-1 p24CA
(monoclonal antibody 183-H12-5C; kindly provided by B
Chesebro through the NIH ARRP), rabbit anti-Hsp90 (Santa
Cruz Biotechnologies), monoclonal mouse anti-HA.11 (Covance),
polyclonal rabbit anti-HA (Rockland) and/or Vpu (rabbit
polyclonal; kindly provided by K. Strebel through the NIH
ARRP [67], and visualized by LiCor apparatus using fluorophores
conjugated secondary antibodies (IRDye 800 Goat anti-rabbit,
IRDye 680 Goat anti-mouse).
One round viral release assay
5610
5 cells (293T/tetherin, Jurkat or CD4+ T cells) were
infected with VSV-G-pseudotyped HIV-1 wt, HIV-1 delVpu or
HIV-1 Vpu ELV at an MOI of 0.5–1. 16 h post infection medium
was replaced and cells (treated or not with 5000 U/ml of universal
type-1 interferon (PBL InterferonSource)) were cultured for a
further 24 h. The cells harvested, the infectivity of viral
supernatants was determined by infecting HeLa-TZMbl and
biochemical analysis of virus particle release was performed as in
Virus release assay. For examining tetherin degradation HT1080
cells stably expressing tetherin-HA were infected with VSV-G-
pseudotyped HIV-1 wt, HIV-1 delVpu or HIV-1 Vpu ELV virus
stocks at a multiplicity of infection (MOI) of 2 to ensure that
approximately 90% of the cells were infected. The medium was
replaced 4 h after infection. 48 h post infection cell lysates were
harvested and processed as described above.
Flow cytometry
HeLa cells were transfected with 400 ng of pCR3.1 GFP and
400 ng of pCR3.1 Vpu-HA or indicated mutants. 48 h post
transfection the cells were harvested and stained for surface
tetherin using a specific anti-BST2 monoclonal IgG2a antibody
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ondary antibody (Molecular Probes, Invitrogen, UK). Tetherin
expression on GFP positive cells was then analyzed using a
FacsCalibur flow-cytometer (Becton Dickinson) and the FlowJo
software. Murine fibroblasts were transduced with the pMigR1-
based retroviral vector pCMS28-IRES-eGFP or a derivative
expressing NL4.3 Vpu. 48 h after transduction the cells were
stained for surface HA versus GFP expression. Jurkat or CD4+ T
cells were infected with VSV-G-pseudotyped HIV-1 wt, HIV-1
delVpu or HIV-1 Vpu ELV at an MOI of 1. 48 h post infection
cells were stained for surface tetherin expression as above, then
fixed and permeabilized for 20 minutes (Cytofix/cytoperm
Fixation/Permeabilization kit, BD Biosciences) and stained for
intracellular HIV-1 p24CA using the KC57 antibody conjugated
to PE (Beckman- Coulter).
Immunofluorescence microscopy
Cells were grown on coverslips and infected with VSV-G-
pseudotyped HIV-1 wt or HIV-1 Vpu ELV, 48 h later cells were
fixed in 4% paraformaldehyde/PBS, washed with 10 mM
glycine/PBS, and permeabilized in 1% bovine serum albumin/
0.1% Tritin-X100/PBS for 15 min. The infected cells were
stained using anti-rabbit polyclonal Vpu in combination with
sheep anti-human TGN46 (AbD Serotec), mouse anti-EEA1 (BD
Biosciences), mouse anti-CD63 (Developmental Studies Hybrid-
oma Bank, University of Iowa) or mouse polyclonal anti-BST-2
(Abnova) followed by the appropriate secondary antibodies
conjugated to Alexa 488 or 594 fluorophores (Molecular Probes,
Invitrogen). The cells were then mounted on glass slides using
ProLong AntiFade- 49,6-diamidino-2-phenylindole (DAPI) mount-
ing solution (Molecular Probes, Invitrogen). Cells were visualized
with a Leica DM-IRE2 confocal microscope. Images were
analyzed using Leica Confocal Software and ImageJ.
Immunoprecipitations
293T cells stably expressing tetherin were transfected twice over
48 h with siRNA oligonucleotide against UBAP1 targeting
CTCGACTATCTCTTTGCACAT or Non-targeting siRNA
was used as control (Dharmacon). The cells were then infected
with VSV-G-pseudotyped HIV-1 wt, HIV-1 delVpu, HIV-1 Vpu
ELV or HIV-1 Vpu A14L,W22A at an MOI of 2. 48 h post
infection the cells were lysed on ice for 30 min in buffer containing
50 mM Tris-HCL pH 7.4, 150 mM NaCl, complete protease
inhibitors (Roche) and 1% digitonin (Calbiochem). After removal
of the nuclei, the supernatants were immunoprecipitated with
5 mg/ml mouse monoclonal anti-BST2 antibody (eBiosciences) for
1.5 h at 4uC. Sepharose-protein G beads were washed in lysis
buffer before they were added to the samples and incubated for
further 3 h. The beads were washed extensively in lysis buffer
containing 0.1% digitonin and resuspended in SDS-PAGE loading
buffer. Cell lysates and immunoprecipitates were subjected to
SDS-PAGE, and Western blot assays were performed using a
rabbit anti-Vpu antibody (kindly provided by K Strebel through
the NIH ARRP), polyclonal rabbit anti-tetherin antibody (kindly
provided by K Strebel through the NIH ARRP) and polyclonal
rabbit anti-UBAP1 antibody (Proteintech), and visualized by
ImageQuant using corresponding HRP-linked secondary antibod-
ies (New England Biolabs, UK). For HRS/Vpu coIP, 293T cells
were co-transfected with 700 ng of pCR3.1 HA-HRS and pCR3.1
Vpu-YFP, pCR3.1 Vpu ELV-YFP or pCR3.1 YFP expression
plasmids. 48 h post transfection the cells were lysed in buffer
containing 0.1 M MES-NaOH pH 6.5, 1 mM magnesium
acetate, 0.5 mM EGTA, 200 mM sodium ortho-vanadate,
10 mM NEM, complete protease inhibitors (Roche) and 1%
digitonin. After removal of the nuclei, the supernatants were
immunoprecipitated with 5 mg/ml monoclonal mouse anti-HA.11
antibody (Covance). Immunoprecipitation was performed as
described above and Western blot assays were performed using
a polyclonal rabbit anti-HA antibody (Rockland) and an anti-Vpu
antibody.
Crosslinking IP
293T cells were co-transfected with 700 ng of pCR3.1 myc b-
TrCP 2 and pCR3.1Vpu-HA, pCR3.1 Vpu ELV-HA, pCR3.1
Vpu 2/6A-HA or pCR3.1 YFP expression plasmids. 48 h post
transfection, Crosslinking Immunoprecipitation was performed as
previously described [68]. Cell lysates and immunoprecipitates
were subjected to SDS-PAGE, and Western blot assays were
performed using a rabbit anti-Vpu antibody and mouse anti-myc
antibody (kindly provided by M. Malim), and visualized by
ImageQuant (GE) using corresponding HRP-linked secondary
antibodies (New England Biolabs).
siRNA-mediated clathrin adaptor knockdown
293T cells stable expressing tetherin or HeLa cells were seeded
at a density of 2610
5 cells per well in a 12 well plate. After 3 h, the
first transfection was performed. For each well, 3 ml Oligofecta-
mine (Invitrogen) was added to 10 ml of Opti-MEM (Life
Technologies), this solution was added to 5 mlo f2 0mM siRNA
in 85 ml of Opti-MEM according to manufactures protocol. For
AP-1 knockdown, HeLa cells stably expressing doxycycline-
inducible pTRIPZ shRNA against AP-1c1 (OpenBiosystems) were
used in combination with siRNA oligonucleotide against AP-1c1
targeting AAGAAGATAGAATTCACCTTT. For AP-2 knock-
down, SMARTpool siRNA targeting the AP-2 m1 subunit was
used (Dharmacon). For AP-3 knockdown, SMARTpool siRNA
targeting the AP-3 m1 subunit was used in combination with
SMARTpool siRNA targeting the AP-3d1 subunit (Dharmacon).
For Vps26 knockdown, siRNA targeting the AACCACC-
TATCCTGATGTTAA sequence was used (Qiagen). On Non-
targeting siRNA was used as control (Dharmafect). The cells were
reseeded into a 24 well plate on day 2 and a second transfection
was performed according to manufactures protocol. The cells were
infected 3 h post transfection with VSV-G-pseudotyped HIV-1 wt,
HIV-1 delVpu at an MOI of 0.8. The infectivity of viral
supernatants was determined by infecting HeLa-TZMbl as
described above. Cell lysates and viral particles were subjected
to SDS-PAGE, and Western blot assays were performed using a
mouse monoclonal AP-1c1 antibody (Sigma), mouse anti-AP50
(AP-2m1) and mouse anti-AP-3d1antibodies (BD Bioscience),
polyclonal rabbit AP-3m1 antibody (kindly provided by M.S.
Robinson) and rabbit polyclonal Vps26 antibody (Abcam).
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Supporting Information
Figure S1 Effect of Vpu helix 2 mutants on surface
tetherin expression in HeLa cells. (A) The full panel of helix
2 alanine scan mutants performed as described for Figure 2D. (B)
HeLa cells were infected with the indicated VSV-G pseudotyped
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surface tetherin and intracellular p24CA. (C) Productively infected
Jurkat cells in Figure 2E were discriminated from those acquiring
p24+ matter from the inoculum by exposing them to the same
dose of wildtype HIV-1 in presence of AZT.
(TIF)
Figure S2 Vpu EXXXL(V/M/I/L) is conserved in most
HIV-1 clades. (A) LogoPlots of Vpu cytoplasmic tail portions
encompassing the conserved phosphorylation motif (DSGNES)
and helix 2 from HIV-1 subgroup M clades A,B,D,G and H
generated from sequences obtained from the Los Alamos database
(www.hiv.lanl.gov). (B) 293T cells were transfected with NL4.3 or
NL4.3 delVpu proviruses in combination with tetherin and Vpu-
HA, Vpu 64I-HA, Vpu 64M-HA or Vpu 64L-HA expression
vectors. 48 h post transfection, cell lysates and pelleted superna-
tant virions were harvested and subjected to SDS-PAGE and
analyzed by Western blotting for HIV-1 p24CA, Vpu-HA and
Hsp90, and analyzed by LiCor quantitative imager. (C) HeLa cells
were co-transfected with Vpu or indicated Vpu mutant and a GFP
expression construct. Cell surface staining for endogenous tetherin
was analyzed by flow cytometry 48 h post transfection, as in
Figure 2D.
(TIF)
Figure S3 Effects of Vpu on surface expression of
human tetherin in murine fibroblasts deficient for AP3
or AP1. Fibroblasts from pearl (AP3d2/2)( A) or AP-1m1A2/2
mice (B) or their reconstituted counterparts were transduced to
express human tetherin bearing an extracellular HA-tag. The cells
were then transduced with retroviral vector constructs encoding
Vpu linked to GFP via an IRES. 48 h later the cells were surface
stained for human tetherin expression using anti-HA antibodies.
(C) HeLa-CD8-CI-M6PR cells were treated with control or Vps26
siRNAs. 48 h later the cells were fixed and stained for CD8 (green)
and TGN46 (red).
(TIF)
Figure S4 Effects of dominant negative dynamin 2 on
Vpu-mediated HIV-1 release. 293T/tetherin cells were
transfected with the indicated HIV-1 provirus and increasing
doses of HA-tagged dominant negative dynamin 2 (A) or the
wildtype protein (B). 48 h later, cell lysates and viral supernatants
were harvested and subjected to SDS-PAGE and analyzed by
Western blotting for HIV-1 p24CA, dynamin 2-HA and Hsp90,
and analyzed by LiCor quantitative imager. Histograms below the
blots indicate particle release efficiency compared to wildtype virus
release in the absence of dynamin 2 or increasing doses of
dynamin 2 expression vector. (C) Corresponding infectivity of viral
supernatants from A and B on HeLa-TZM cells alongside those
from a parallel experiment in parental 293T cells. (D) 293T/
tetherin cells were transfected with pCR3.1 YFP with or without
increasing doses of dominant negative dynamin 2. 48 h later the
cells were starved in serum-free medium for 30 minutes and then
treated for a further 15 minutes with 10 mg/ml Alexa-594-
conjugated transferrin, before fixation and imaging.
(TIF)
Figure S5 Effect ELV mutant on HIV-1 infectious
release from HeLa cells. HeLa cells were infected with
VSV-G pseudotyped stocks of the indicated virus at an MOI of
0.5. 48 h later the cell supernatants were harvested and infectivity
determined on HeLa-TZM cells.
(TIF)
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